Matinas BioPharma to Merge with GH Power, Sell Drug Asset to Azurity

Matinas BioPharma announced a two-part strategic overhaul Wednesday, signing a definitive agreement to merge with GH Power in a business combination designed to create a publicly traded clean energy company, while simultaneously agreeing to sell its lipid nanocrystal drug delivery platform and lead pharmaceutical candidate MAT2203 to Azurity Pharmaceuticals.

The merged entity with GH Power will concentrate on modular carbon-free energy solutions, green hydrogen production, critical materials sourcing, and industrial decarbonization — sectors that have attracted intensifying investor interest as governments and corporations race to meet emissions-reduction targets. The combined company is expected to trade publicly, giving retail and institutional investors direct exposure to the emerging green hydrogen space through an established market vehicle.

Read more Four AI-Powered SRE Tools Worth Using in 2025 →

By shedding its LNC platform technology and MAT2203 — a lead antifungal candidate that had been Matinas's primary clinical asset — to Azurity, the company effectively completes a full-sector exit from biopharmaceuticals. The move signals that Matinas leadership sees greater long-term value creation in clean energy infrastructure than in advancing a drug pipeline, a significant strategic bet given the capital-intensive nature of energy development.

The dual transaction reframes what had been a clinical-stage biotech into a vehicle for the energy transition, a repositioning that will require shareholder approval and regulatory clearance before closing. Investors will be watching closely to see whether the new clean energy focus can justify the departure from Matinas's original scientific mission and deliver returns competitive with dedicated energy-sector peers.

Continue reading at GlobalNewswire.